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Background: Severe malaria results in over a million deaths every year, most of them in children aged less than
five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for
severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel
good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug
use and distribution by the CDC.
Methods: Tolerability and pharmacokinetics of current GMP intravenous AS, as an anti-malarial agent, were
evaluated after ascending multiple doses of 2, 4, and 8 mg/kg daily for three days with 2-minute infusion in 24
healthy subjects (divided into three groups) in the Phase 1 clinical trial study.
Results: Results showed that there were no dose-dependent increases in any adverse events. Drug concentrations
showed no accumulation and no decline of the drug during the three days of treatment. After intravenous
injection, parent drug rapidly declined and was converted to dihydroartemisinin (DHA) with overall mean
elimination half-lives ranging 0.15-0.23 hr for AS and 1.23-1.63 hr for DHA, but the peak concentration (Cmax) of AS
was much higher than that of DHA with a range of 3.08-3.78-folds. In addition, the AUC and Cmax values of AS and
DHA were increased proportionally to the AS climbing multiple doses.
Discussion: The safety of injectable AS, even at the highest dose of 8 mg/kg increases the probability of
therapeutic success of the drug even in patients with large variability of parasitaemia.
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Artemisinin and its derivative act rapidly against drug-
resistant Plasmodium falciparum strains, and are widely
used for the treatment of various malarias in humans.
Dihydroartemisinin (DHA) is originally obtained by so-
dium borohydride reduction of artemisinin, an endoper-
oxide containing sesquiterpene lactone, which was
isolated by Chinese researchers and characterized as
the antimalarial principle of the plant Artemisia annua.
In vitro bioassay tests have shown DHA to be more* Correspondence: qigui.li@us.army.mil
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reproduction in any medium, provided the orpotent than artemisinin. DHA is similar to artesunate
(AS) [1] and three to five-fold more active and more
toxic than other artemisinin derivatives [2,3]. It can com-
pletely inhibit parasite growth within two to four hours,
and is the only artemisinin derivative with activity
against all asexual blood stage parasites [4]. The excellent
effectiveness of AS by rapid parasite and fever clearance
has been mostly attributed to its rapid and extensive
hydrolysis to DHA [5-8].
Artemisinins have been used in malaria treatment as
monotherapy since 1983. However, monotherapy with
artemisinin derivatives was significantly discouraged
after 2001 to prevent the emergence of resistance, and
the new policy is to treat non-severe malaria with arte-
misinin derivatives in combination with other anti-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, intravenous AS, as initial monotherapy, is still a
first-line treatment for both adults and children in Asian
countries [9] and some areas in Africa [10]. Severe mal-
aria is generally defined as acute malaria with major
signs of organ dysfunction or high levels of parasitemia.
Severe malaria, if not treated, results in 100% mortality
[11]. Practically though, severe malaria can be defined as
acute malaria where the patient cannot take oral medica-
tions to effect a cure. In areas where malaria is endemic,
young children and pregnant women are at high risk of
severe malaria. It is fundamental that plasma concentra-
tions of a highly effective anti-malarial drug are achieved
as rapidly as possible.
After recent clinical studies with severe malaria
patients, intravenous AS was determined to be the drug
with the highest treatment success and the lowest inci-
dence of adverse events [9,12,13]. The two largest trials
ever conducted for severe malaria in endemic regions
showed that, in both adults and children, treatment with
intravenous AS is superior to intravenous quinine. The
mortality rate among quinine-treated patients was 22%
and 10.9% in the SEAQUAMAT and AQUAMAT studies
respectively; for AS this was 15% and 8.5%, a significant
reduction of 35% and 22.5% respectively [13,14]. Patients
with hyperparasitaemia (>10% of RBC) had a signifi-
cantly greater treatment effect with AS than non-
hyperparasitaemia patients. Intravenous AS was also bet-
ter tolerated, safer and easier to use than quinine. The
life-saving benefit of AS in severe malaria was recog-
nized by WHO in 2006 and since then intravenous AS
has been the treatment of choice for severe falciparum
malaria [12,13].
Many other clinical studies for pharmacokinetic
evaluation of AS have been conducted, mostly in Asia
and Africa [15]. Peak concentration (Cmax) has been
demonstrated to be more important than AUC in pro-
ducing the improved efficacy of anti-malarial drugs as
outlined in previous pharmacokinetics (PK) and
pharmacodynamics (PD) evaluation [16]. The AS, which
is the only artemisinin derivative clinically available as
an injectable formulation, can provide sufficiently high
peak concentrations in the patients and can provide the
most rapid efficacy in parasite killing, showing that in-
jectable AS is pharmacokinetically and pharmacodyna-
mically superior when compared to other artemisinins
[16]. Therefore, AS monotherapy is still needed, if only
for this single niche indication [17,18].
The Chinese manufacturer (Guilin Pharmaceutical
Company Ltd, Shanghai, China) of the product that was
used in most of the clinical trial studies and treatment
cases recently improved the production process, with
support of the Medicines for Malaria Venture (MMV).
However, only intravenous quinine or quinidine is stillused in Europe and the USA because the main barrier
for the use of intravenous AS is the absence of a prod-
uct that is manufactured under good manufacturing
practices (GMP). Since 2004, the Walter Reed Army In-
stitute of Research (WRAIR) has been developing a
novel GMP injection of AS, which was approved by the
US FDA for investigational drug use and distribution by
the CDC [19]. As previously reported, a Phase 1a clin-
ical trial of this GMP product was conducted, with sin-
gle dose (0.5, 1, 2, 4, and 8 mg/kg) administration of
intravenous artesunate studied in 40 healthy volunteers
[20]. The present Phase 1b study (ClinicalTrials.gov
Identifier: NCT00292942) describes the PK of injectable
AS, using escalating multiple doses in healthy volun-
teers daily for three days with the aim of developing a
safe and feasible dose.
Methods
Chemicals
The bulk artesunic acid [4-(10’dihydro-artemisinin-oxy-
methyl) succinate] substance was purchased from Knoll
AG (Switzerland). BASF Pharmaceuticals rebottled it
from the original company (GMP). The clinical trial AS
(Batch #: 14462–16) has been tested for sterility and
short-term stability. The formulation is contained in
sterilized bottles with 110 mg artesunic acid per bottle.
The injection buffer for AS is manufactured as a GMP
phosphate salt with 0.3 M PBS (pH 8.0) and provided by
Stanford Research Institute (Menlo Park, CA, USA). The
multiple dosage form for the Phase 1 clinical trial was
manufactured to be prepared as follows: 110 mg by re-
constitution in 11 ml of this buffer (10 mg/ml) to make
a fresh stock solution sufficient to dose all the volunteers
scheduled daily on three given days.
Subject background
For confirmation of their health status, all subjects were
selected to be healthy adult males (seventeen) and non-
pregnant, non-lactating females (seven) and were
assessed by inspecting their full clinical history and con-
ducting appropriate examinations, including clinical la-
boratory evaluations (clinical chemistry, haematology
and urinalysis), thyroid stimulating hormone, free T4,
electrocardiograms, and blood pressure before entry into
the study. Subjects were also checked for their body
mass index (BMI) which was ideally between 18 and
29 kg/m2 and, if out of this range, their weight needed
to be "not clinically significant" or within 15% of their
ideal body weight. All subjects gave written informed
consent.
Study design
The study was a double blind, ascending multiple doses,
alternating group, safety, tolerance, and PK study.
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intravenously to three groups of the subjects using alter-
nating doses of 2, 4, and 8 mg. All eight subjects in each
dose group received either the AS (six subjects) or pla-
cebo (two subjects) in a pre-randomized manner. The
study physician, after verifying the code with a study
nurse, would then inject either the drug or placebo into
an injection port at the pre-measured dose over about
2 min as a short-term intravenous infusion; the study
nurse recorded the time of study drug reconstitution, in-
fusion start and completion of injection. When the injec-
tion was completed, the study nurse recorded tolerance
of injection to include both inspection of site and sub-
jects’ responses. Subjects were provided a light lunch at
approximately 4 hours after dosing. Normal activities,
excluding strenuous exercise, were permitted four hours
after dosing. Blood samples for the measurements of AS
and DHA levels in plasma was approximately 10 min be-
fore dosing (0 h), and at 5, 20, 40 min, 1, 2, 4, 6, and 8 h
on days 1, 2, and 3 post-dose. During the multiple-dose
period, samples were collected immediately before
morning dose on days 2 and 3 for additional trough
values. All the samples were stored at −80 °C until ship-
ment and were then shipped to a bio-analytical GLP la-
boratory, Midwest Research Institute (MRI), in Kansas
City, MO, USA. The human use protocol numbers for
the Phase 1 trial are: USUHS #G183RW; WRIAR #1128;
and HSRRB #A-13276.
LC-MS/MS assay
An LC-MS/MS method for the quantitation of AS and
DHA (50–100 μl) in human plasma was validated from
2 to 400 ng/ml for AS and DHA. The analytes were
extracted from human plasma with ethyl acetate. These
extracts were dried and reconstituted in 50:50 (v/v)
acetonitrile: water containing indomethacin as the in-
ternal standard. The reconstituted extracts were ana-
lysed on a Micromass Quattro II Mass Spectrometer in
the positive ion electrospray ionization (+ESI) mode.
The compounds of AS, DHA, and internal standard,
indomethacin, were monitored in the multiple reaction
monitoring (MRM) mode. This method employed a Var-
ian Pursuit C18 column (150 x 2.0 mm, 5-μm particle
size) and a gradient elution with the following mobile
phases: A: 10 mM ammonium acetate in water with 1%
formic acid and B: 10 mM ammonium acetate in aceto-
nitrile with 1% formic acid, for the chromatographic
separation.
Standard curve and quality control (QC) samples were
generated by spiking interference-free human plasma
samples with known amounts of AS, DHA, and internal
standard. The drug concentrations of the QC samples
chosen were within the range of the standard curve,
and included a lower limit of quantification (LLOQ),low (<3 x LLOQ), medium, and high QC levels. The
limit of quantification was 3.4-4.3 ng/ml for AS and
1.7-2.6 ng/ml for DHA. The peak area ratios (PARs)
of AS (product at m/z 163.13, from parent ion at
m/z 402.10, collision energy 26 V) and DHA (product at
m/z 163.13, from parent ion at m/z 302.10, collision
energy 20 V) to indomethacin internal standard (product
at m/z 139.00, from parent ion at m/z 358.00, collision
energy 37 V) were calculated for each sample from the
measured peak areas obtained by LC-SRM. Drug concen-
trations in QC samples and experimental rat plasma sam-
ples were calculated by this best-fit equation and the
PARs obtained from the LC-MS/MS analysis. Calibration
standards and QC samples were analysed to evaluate the
performance of the assay.
Compartmental analysis (CA) of artesunate
Compartmental (model-dependent) and non-compartment
(model-independent) PK analysis are common methods to
determine PK parameters, which are acceptable by FDA
[21]. In order to compare only the clinically relevant con-
centrations, the compartmental PK analysis was selected
for PK analysis in this study and based on a short-term
(2 min) intravenous infusion in accordance with a previous
PK evaluation [20]. Injectable AS disposition was best
described by a two-compartment model with a rapid initial
distribution phase after intravenous administration. The
input of the drug was assumed to follow zero-order kinet-
ics, and elimination from the central compartment oc-
curred with first-order kinetics. Compartmental analysis of
concentration-time data for parent drug was performed
using the WinNonlin software with an intravenous infu-
sion program. The first-order method with logarithmic
transformation of all drug-concentration data was used
throughout.
The drug plasma concentrations at the end of an intra-
venous (IV) infusion (Cmax) were calculated from the
corresponding model equations (IV-infusion model,
WinNonlin) at the respective time points. The AUC(0-t)
(where t = the time point for the last sample on the PK
profile in which quantifiable drug was detected) was esti-
mated using linear or linear/log trapezoidal calculations.
The Cmax and the time to maximum drug concentration
(tmax) were obtained from the experimental values and
the predicted AS concentration at the end of the infu-
sion (2 min) was calculated by compartmental model-
ling. The values of the following PK parameters were
derived by a compartmental method for AS with Win-
Nonlin Version 5.2: half-life (t½); mean residence time
(MRT); the AUC from time zero to the last sampling
time (AUCt); the AUC from time zero extrapolated to
infinity (AUC∞); total systemic clearance (CL); and
volume of distribution during steady state (Vss), which
was obtained by adding the volumes of the different
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index was estimated from the AUC values on day 3
(last multiple dose administration) divided by the AUC
on day 1 (first multiple dose administration).
Non-compartmental analysis (NCA) of dihydroartemisinin
Previous PK analysis confirmed that the PK parameters
of DHA showed no significant differences in Cmax, AUC,
and total clearance over bioavailability (CL/F) between
the NCA and CA analyses, indicating that the PK mod-
elling for DHA is model-independent [20]. Therefore, in
the present report the non-compartmental method is
suitable for DHA. The maximum concentration in
plasma for each subject was read directly from the ex-
perimental values. For the determination of initial ap-
proach to PK parameters of DHA in plasma after
systemic application, a non-compartmental analysis was
performed using WinNonlin (version 5.2; Pharsight
Corp, Mountain View, CA, USA). The values of the
following PK parameters were derived by a non-
compartmental method: the half-life (t½); mean resi-
dence time (MRT); the AUC from time zero to the last
sampling time (AUCt); the AUC from time zero extra-
polated to infinity (AUCinf ); relative total systemic clear-
ance (CL/F_obs); and volume of distribution during
steady state (Vss/F_obs). A drug accumulation index was
estimated from the AUC value on day 3 divided by the
AUC value on day 1 (first multiple dose administration).
The AUCinf ratios of the metabolite to the parent com-
pound AS were calculated to determine exposure to
any metabolite compared with the parent drug.
Other data evaluation
Statistical analysis was conducted with Microsoft Excel
using a Student's t-test for dependent samples to com-
pare means of paired samples between groups. A drug
comparison of day 3 AUC value vs. day 1 AUC for each
dosing group was estimated. The accumulation index of
plasma concentration was calculated at steady state
compared to the first dose.
Results
Intravenous AS manufactured to be cGMP compliant
(currently available through the CDC) was provided to
24 healthy volunteers aged 20–55 years (mean ± SD:
36.1 ± 12.4) and weighing 78.4 ± 13.2 kg who were en-
rolled in this study.
Tolerability and safety
In this study, 24 healthy volunteers divided into three
groups were treated with multiple intravenous infusions
(a total of three doses) of AS with PBS buffer, and six
volunteers were administered the same volume of ve-
hicle. For each subject, adverse events (AEs) wererecorded throughout the post-dosing period. Daily intra-
venous treatments with the WRAIR formulation of AS
for three days were well tolerated in healthy volunteers
at doses up to 8 mg/kg. There were no subject drop-
outs for adverse events or other treatment related issues.
A dose-related decrease in reticulocyte count was noted
that peaked four days after dosing and returned to nor-
mal by study day 7 in most cases, and day 10 in all
patients. There were no other clinically significant la-
boratory abnormalities detected. No deleterious haemo-
dynamic or ECG effects were seen. A transient,
reversible sensation of altered or unusual taste, which
lasted less than 30 minutes in all cases, was associated
with higher doses of AS. All remaining side effects were
generally mild and all were reversible.
Compartmental analysis of artesunate
WinNonlin analysis resulted in a two-compartment
model of intravenous infusion with first-order elimin-
ation, which best fitted the set of observations of intra-
venous AS in the present trials [20]. The plasma
concentration and the final PK parameters estimates for
the IV infusion in two-compartment model at daily dose
of 2, 4, and 8 mg/kg for three days are shown in Figure 1
and Table 1, respectively. After the day 1 short term infu-
sion (2 min), high plasma peak concentrations (Cmax)
were reached, with mean Cmax values ranging from
28411 ng/ml for the 2 mg/kg dose cohort to 63677 ng/ml
for the 8 mg/kg dose cohort. The mean Cmax and AUCinf
for AS in the subjects with the higher dose were roughly
double when going from the 2 to the 4 mg/kg cohort and
again when going from the 4 to the 8 mg/kg cohort and
increased in proportion (r2 = 0.910-0.961) to the dose in
all three dose groups (Figure 2, top).
After the injection of 2 mg/kg of AS daily for three
days, the mean AUC obtained with these doses ranged
from 2,051 ngh/ml on day 1 to 1,270 ngh/ml on day 3
with a mild decrease, but no significant change statisti-
cally (p = 0.104), and the accumulation index was 0.81
(Table 1). Similar data were found in the groups of 4
and 8 mg/kg volunteers, and the accumulation indices
were 0.80 for the 4 mg/kg subjects and 1.01 for the
8 mg/kg volunteers. No statistically significant variations
(p > 0.289) of the accumulation or reduction of AS con-
centration were observed on day 3 in comparison to day
1 of treatment in plasma. The mean elimination half-
lives ranged between 0.15 and 0.21 hr, and the mean
residence time ranged from 0.07 and 0.08 hr during the
three days of treatment following 2, 4, and 8 mg/kg
doses injected (Table 1). Plasma total clearance (Cl) and
volume of distribution during steady state (Vss) were all
in a similar range without significant variation. Based on
previous infusion PK analysis [20], the PK results indi-
cated that the parameters of AS can be calculated only
Figure 1 (See legend on next page.)
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Figure 1 Mean plasma concentration-time profiles of artesunate (AS, left) and dihydroartemisinin (DHA, right), an active metabolite of
AS, measured by LC-MS/MS (markers) and computer pharmacokinetic fitting curves (solid-line) following multiple intravenous dosage
with 2 min short-term infusion of AS at 2 (top), 4 (middle), and 8 (bottom) mg/kg in healthy volunteers. (n = 6 for each dose cohort).
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dependent.
Non-compartmental analysis of dihydroartemisinin
The plasma concentrations of DHA, an active metabol-
ite of AS, after short-term infusion at multiple doses of
2, 4, and 8 mg/kg are shown in Figure 1. Table 2 shows
the mean parameters (CV%) in a first approach for the
non-compartmental analysis (NCA). The mean Cmax
and AUCinf for DHA were increased in a dose-
dependent manner in all three dose cohorts. Mean peak
concentrations of DHA over the three days ranged from
1735–2358 ng/ml in the 2 mg/kg cohort, 2923–Table 1 Mean (CV%) pharmacokinetic parameters of artesuna
(CA) following multiple intravenous administrations of 2, 4, a
(2 min) in healthy volunteers (n =6 per group)*
Date of dose PK Parameters 2 m
Day 1 Cmax (ng/ml) 284
Tmax (min) 2
AUCinf (ngh/ml) 205




Day 2 Cmax (ng/ml) 179
Tmax (min) 2
AUCinf (ngh/ml) 141




Day 3 Cmax (ng/ml) 164
Tmax (min) 2
AUCinf (ngh/ml) 127




Accumulation Index (AUCD3/D1) 0.81
P value (T-Test, AUCD3:D1) 0.10
Total AUCD1-D3 (ngh/ml) 473
Data are presented as arithmetic mean (CV%); NCA=non-compartment analysis (W
CA= compartment analysis (WinNonlin 5.2 Version with compartment model 10, IV-3018 ng/ml in the 4 mg/kg cohort, and 5762–6056 ng/
ml in the 8 mg/kg cohort. Mean AUCinf values over
three days ranged from 2021–2385 ngh/ml in the
2 mg/kg cohort, 3740–4391 ngh/ml in the 4 mg/kg co-
hort, and 8732–9697 ngh/ml in the 8 mg/kg cohort
(Table 2). In no cohort were statistically significant Cmax
and AUC differences observed between Day 1 and Day
3 (Table 2). Mean Tmax was revealed to fall in a range of
0.16-0.29 hr and the elimination t1/2 s was in a range of
1.19-1.91 hr. The mean body clearance over bioavailabil-
ity (CL/F) and volume of distribution at steady state
over bioavailability (Vss/F) ranged from 14.63-19.37 ml/
min/kg and 1,691-2,377 ml/kg, respectively. A dose-te (AS) by intravenous-infusion compartment modeling
nd 8 mg/kg daily for 3 days with a short-term infusion
g/kg (n = 6) 4 mg/kg (n = 6) 8 mg/kg (n= 6)
11 (59) 40574 (68) 63677 (55)
2 2
1 (66) 4640 (69) 6022 (48)
(52) 0.21 (46) 0.20 (40)
9 (33) 19.39 (48) 27.87 (51)
.60 (48) 104.34 (80) 187.99 (89)
(47) 0.08 (38) 0.10 (37)
20 (57) 34387 (50) 74588 (45)
2 2
0 (49) 2628 (30) 6669 (47)
(51) 0.23 (67) 0.19 (19)
0 (45) 27.26 (28) 26.66 (64)
.24 (57) 139.76 (51) 129.10 (68)
(35) 0.08 (29) 0.08 (8)
87 (42) 51164 (61) 67613 (83)
2 2
0 (26) 3518 (51) 5916 (61)
(40) 0.20 (46) 0.20 (60)
7 (26) 23.02 (35) 28.91 (44)
.00 (42) 122.17 (49) 164.58 (55)
(18) 0.08 (42) 0.09 (24)
(56) 0.91 (45) 1.01 (31)
4 0.289 0.459
1 (40) 10787 (17) 18606 (45)
inNonlin 5.2 Version with non-compartment model 202, IV-infusion);
infusion); MRT =mean residence time.
Figure 2 Correlations (r2 = 0.910-0.986) are shown between multiple intravenous doses and peak concentration (Cmax) or area under
the curve (AUC) with artesunate (AS) or dihydroartemisinin (DHA), an active metabolite from AS. A: mean samples (markers) were taken
from Cmax of AS; B: mean values were taken from AUC of AS; C: mean samples were taken from Cmax of DHA; and D: mean values were taken
from AUC of DHA in all three dose groups (2, 4, and 8 mg/kg) after AS treatments daily for three days. The line represents linear regression
whose statistical parameters are shown in the inset (A-D).
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subjects were shown to correlate well (r2 = 0.983-0.986)
to the dose in all three dose cohorts (Figure 2).
Pharmacokinetic comparison of artesunate and
dihydroartemisinin parameters
The conversion data of AS to DHA is presented in
Table 2. In all three dose cohorts, the plasma concentra-
tion (AUC) of DHA was more than that of AS with a
range of 1.15-1.65 ratio of AUCDHA/AS, but the peak
concentration (Cmax) of AS was much higher than that
of DHA with a range of 3.08-3.78 ratio of Cmax AS/DHA.
DHA also revealed a longer half-life of 1.19-1.91 hr,
which was 7.8 – 8.2 fold longer than shorter half-lives of
AS with 0.15 – 0.21 hr. If the AUC values of AS and
DHA were combined, the total combined AUC calcu-
lated was increased proportionally to the AS climbing
doses as well in all three dose cohorts (Table 2).Discussion
In this study, the PK and possible side effects of an
intravenous infusion of AS were investigated in healthy
volunteers. Up to the highest dose of 8 mg/kg daily for
three days, intravenous AS was well tolerated and no
serious side effects were observed. A dose-related de-
crease in reticulocyte count was noted that peaked four
days after dosing and returned to normal by study day
7 in most cases. There were no other clinically signifi-
cant laboratory abnormalities detected. No deleterious
haemodynamic or ECG effects were seen.
Two methods to determine PK parameters are the com-
partmental (model-dependent) and non-compartment
(model-independent) PK analyses, which are perfectly ac-
ceptable by the US FDA for new drug application [21]. In
a previous clinical trial [20], PK evaluation with both
non-compartmental analysis (NCA) and compartment
analysis (CA) were performed for both AS and its active
Table 2 Mean (CV%) PK parameters of dihydroartemisinin (DHA), an active metabolite of artesunate (AS), by non-
compartment analysis (NCA) following multiple intravenous administrations of AS at dose 2, 4, and 8 mg/kg daily for
3 days with a short-term infusion (2 min) in healthy volunteers* (n =6 per group)
Date of dose PK Parameters 2 mg/kg (n = 6) 4 mg/kg (n = 6) 8 mg/kg (n= 6)
Day 1 Cmax (ng/ml) 1735 (31) 3015 (29) 6056 (40)
Tmax (hr) 0.29 (45) 0.25 (55) 0.25 (59)
AUCinf (ngh/ml) 2121 (18) 4391 (22) 9697 (37)
t1/2 elimination (h) 1.19 (16) 1.74 (59) 1.42 (21)
CL/F (ml/min/kg) 16.18 (19) 15.92 (26) 15.51 (37)
Vss/F (ml/kg) 1634 (14) 2377 (62) 1870 (39)
MRT (h) 1.41 (12) 1.91 (22) 1.81 (16)
Day 2 Cmax (ng/ml) 1710 (41) 2923 (35) 5943 (35)
Tmax (hr) 0.20 (63) 0.25 (55) 0.22 (69)
AUCinf (ngh/ml) 2012 (27) 3740 (28) 8732 (35)
t1/2 elimination (h) 1.59 (55) 1.42 (22) 1.91 (60)
CL/F (ml/min/kg) 17.55 (24) 19.37 (35) 16.96 (35)
Vss/F (ml/kg) 2224 (31) 2249 (21) 2525 (35)
MRT (h) 1.53 (24) 1.65 (20) 2.09 (36)
Day 3 Cmax (ng/ml) 2358 (26) 3018 (25) 5762 (59)
Tmax (hr) 0.16 (63) 0.29 (45) 0.29 (45)
AUCinf (ngh/ml) 2385 (24) 3960 (19) 9205 (33)
t1/2 elimination (h) 1.31 (16) 1.24 (20) 1.34 (12)
CL/F (ml/min/kg) 14.63 (22) 17.49 (23) 15.60 (27)
Vss/F (ml/kg) 1691 (33) 1895 (34) 1776 (25)
MRT (h) 1.39 (6) 1.57 (16) 1.78 (11)
Accumulation Index(AUCD3/D1) 1.14 (21) 0.93 (24) 0.98 (15)
P value (T-Test, AUCD3:D1) 0.140 0.157 0.233
Total AUCD1-D3 6520 (18) 12092 (20) 27635 (34)
Ratio of AUCDHA/AUCAS 1.46 (23) 1.15 (28) 1.65 (39)
Ratio of Cmax AS/Cmax DHA 3.08 (45) 3.71 (47) 3.78 (49)
Data are presented as arithmetic mean (CV%); NCA=non-compartment analysis (WinNonlin 5.2 Version with non-compartment model 202, IV-infusion);
CA = compartment analysis (WinNonlin 5.2 Version with compartment model 10, IV-infusion); MRT =mean residence time.
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parameters of DHA there were no significant differences
in Cmax, AUC, and other parameters between the NCA
and CA analyses, indicating that the PK modelling for
DHA is model-independent. This suggests that either
modelling method can be used for PK analysis. However,
it is not suitable for the PK evaluation of AS with a
short-term intravenous infusion. When using NCA for
the parent drug, the AUC calculation of AS will lose the
contribution of the Cmax at the end of the infusion at
two minutes because the Cmax was only estimated by a
compartmental model of IV-infusion at the ending time
of infusion. In the previous report, the AUC was under
calculated by 28-40% using the NCA method when
compared to CA analysis [20]. Therefore, only CA ana-
lysis can fulfill the PK evaluation of AS with the infusion
administration. After comparison to the NCA modellingmethod, the two-compartment, IV-infusion model was
appropriately described by the disposition PK data of
intravenous AS, which should be fitted in the present
study by a model-dependent algorithm.
Similar to the literature, the results showed that AS is
rapidly converted to DHA, which was detected in all
volunteers' plasma until six hours, while the parent drug
was undetectable at timepoints as early as one to two hr
after each short-term infusion. In vitro, DHA is similar
to AS [1], and three to five-fold more active and more
toxic than the other artemisinin derivatives [1,2]. Al-
though the plasma concentration of DHA was superior
to that of AS with a range of 1.15 to 1.65 ratio of
AUCDHA/AS, the peak concentration of AS was higher
than that of DHA with 3.08 to 3.78 ratio of Cmax AS/
Cmax DHA (Table 2). It is known that DHA has a longer
half-life of 1.23 to 1.63 hr, which is 7.8 to 8.2-fold longer
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http://www.malariajournal.com/content/11/1/255than AS with a short half-life of 0.15 to 0.21 hr. There-
fore, the effectiveness of AS has been attributed to itself
and to its rapid and extensive hydrolysis to DHA [5-8].
Mean AUC of AS obtained with these doses ranged on
day 3 from 1,270-5,916 ngh/ml, which was less than
that observed on day 1 (2,051-6,022 ngh/ml), but no
significant change was shown in these data statistically.
Likewise for DHA, no significant change of AUCs was
found between day 3 (2,385-9,205 ngh/ml) and day 1
(2,121-9,697 ngh/ml) following the multiple intravenous
injections. These results indicate that no significant
plasma concentration was found in these healthy volun-
teers after the administration of three intravenous doses
due to only three days dosing with low power in the
present study. However, after oral dosing, four artemisi-
nin drugs (artemisinin, artemether, AS, and DHA) have
revealed declining concentrations in plasma during mul-
tiple treatments in malaria patients and healthy subjects.
The Cmax and AUC values for AS were markedly
reduced, about one-third to one-seventh on the last dose
day as compared to the first day with minimal 5 days
dosing [22-26]. The decrease in plasma concentration
time during multiple treatments is indicative of an in-
crease in metabolic capacity due to auto-induction of
hepatic drug-metabolizing enzymes in patients [22,23]
and in healthy subjects [24-26].
In the present report, the peak concentration (Cmax) of
AS was much higher than that of DHA with a range of
3.08–3.78 ratio of Cmax AS/DHA. The high peak concen-
trations with these doses (16,487-74,588 ng/ml) of AS
provide a great advantage to rapidly kill malaria para-
sites. PK/PD evaluations demonstrate that the rapid effi-
cacy of artemisinins is principally due to the drug peak
concentration (Cmax) because only correlative with para-
site killing is the peak concentration among the five arte-
misinins, indicating AS is superior in terms of both PK
and PD following either oral or intravenous administra-
tion. Other pharmacokinetic parameters, such as drug
exposure level (AUC) and drug exposure time (half-life)
were not correlated to the parasite killing and tend to be
of minor importance [15,16]. More clinical observations
have been reported demonstrating the fast pharmacody-
namic properties of these artemisinins have been rela-
tively addressed with a PK/PD evaluation [27,28].
In the previous clinical trials, the mean peak level
(Cmax) of intravenous AS was achieved at 11,343 ng/ml
and reduced the duration of the lag phase of the parasit-
aemia curve to 1.92 hr, which was vastly decreased when
compared with oral AS with Cmax of 1052 ng/ml
(2.81 hr lag time) and the other four artemisinins (4.03-
8.89 hr lag time) with Cmax range of 74.9 – 588.0 ng/ml
[15]. The summary indicated that the parasite-killing ef-
fect of AS injection was very fast and efficient showing a
mean time of 3.18 hr for clearance of half theparasitaemia (PC50), the lowest PC50 when compared to
oral AS and other artemisinins, which demonstrated a
PC50 of 8.48-19.68 hr. Oral AS and the other four arte-
misinins (oral DHA, oral artemisinin, intramuscular
artemether and arteether) showed a slower killing effi-
cacy because their administration resulted in a lower
peak concentration ranging from 74.9-1,052 ng/ml
[15,16].
These facts together indicate that AS is a superior
anti-malarial agent in terms of PK/PD performance.
Intravenous AS can provide the highest peak concentra-
tion and a very short exposure time, while oral AS can
also provide higher peak level and short exposure times;
the higher peak level of injectable AS plays a role in
parasite elimination rapidly and the short exposure time
allows patients to avoid fatal neurotoxicity [29], and also
prevents the rise of parasite resistance [30]. All of the
evidence shows that higher plasma concentration (Cmax
and AUC), especially the peak concentration (Cmax), will
greatly increase the efficacy and clinical therapeutic po-
tential of artemisinin drugs. As discussed above, from
the severity of these complications, P. falciparum mal-
aria constitutes a medical emergency, and appropriate
treatment should be initiated as soon as infection is sus-
pected. This study suggests that intravenous high dose
AS therapy is most appropriate treatment for patients
with severe malaria. It is known that 84% of all malaria-
related deaths occur within 24 hours of hospital admis-
sion in African children [31]. Therefore, first exposure
concentrations of artemisinin drugs are clinically very
important.
In conclusion, the study presented here underlines the
need for appropriate PK analysis of AS and its metabol-
ite, DHA. Due to a short-term duration of intravenous
infusion, PK analyses of the data observed after intraven-
ous AS administration is more suitably fitted to model-
dependent rather than model-independent algorithms.
Injectable AS is a superior anti-malarial agent in terms
of PK performance with the highest peak concentration
and the shortest exposure time. The higher peak level of
AS concentration plays a crucial role in eliminating
parasites rapidly and the short exposure time allows
patients to avoid fatal neurotoxicity. The present data
show that the administration of injectable AS at a high
dose of 8 mg/kg is safe, and the use of higher doses may
increase the probability of success when used in patients
with larger variability in PK and PD [16,32].
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